CDC and PHE recommendations for the antiviral treatment and prophylaxis of influenza
More details
Hide details
First Academic Department of Pneumonology, Hospital for Diseases of the Chest, “Sotiria”, Medical School, National and Kapodistrian University of Athens, Athens, Greece
Demosthenes Bouros   

Hospital for Chest Diseases "SOTIRIA" 152 Messogion Av., Athens 11527, Greece
Publication date: 2021-06-16
Pneumon 2016;29(4):282–287
Influenza is a major cause of severe respiratory infections with excessive morbidity and mortality globally. Annual epidemics or pandemics still exert a major health and socioeconomic burden. Vaccination remains the principal means for preventing influenzarelated morbidity and mortality. However, antiviral agents present with major beneficial effects since they could improve viral clearance, shorten illness duration and hospitalizations, diminish complications, reduce death risks and limit disease transmission. Decisions about starting antiviral treatment should not wait for test results or laboratory confirmation of influenza. When there is clinical suspicion of influenza and antiviral treatment is indicated, antiviral treatment should be started within 48 hours after the symptom onset. Oral oseltamivir for 5 days represent the optimal therapeutic regimen for both prophylaxis and treatment of influenza infection. Inhaled zanamivir is the first line of treatment for influenza infection (complicated or uncomplicated) in immunocompromised individuals or in cases of confirmed H1N1 infections with suspected resistance to oseltamivir. This short review summarizes the current Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control (CDC) and the Public Health England (PHE) recommendations for the antiviral treatment and prophylaxis of influenza infection.
No conflict of interest to declare
Antiviral Agents for the Treatment and Chemoprophylaxis of Influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). CDC. Morbidity and Mortality weekly report. 2011; 60: No1.
PHE guidance on use of antiviral agents for the treatment and prophylaxis of influenza (2016-17). Version 7.0 Public Health England. October 2016 schema.
Duque J, McMorrow ML, Cohen AL. Influenza vaccines and influenza antiviral drugs in Africa: are they available and do guidelines for their use exist? BMC Public Health 2014; 14: 41.
Angela Campbell. CDC Expert Commentary. 2016-2017 Influenza Antiviral Recommendations Medscape January 09, 2017.
CDC. What You Should Know About Flu Antiviral Drugs.
Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet 2015; 385: 1729-1737.
Jefferson T, Jones M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. Bmj 2014; 348: g2545.
Hernandez JE, Adiga R, Armstrong R, et al, e INDPI. Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an Emergency IND program in the United States. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2011; 52: 695-706.
Matheson NJ, Harnden AR, Perera R, Sheikh A, SymmondsAbrahams M. Neuraminidase inhibitors for preventing and treating influenza in children. The Cochrane database of systematic reviews 2007: CD002744.
Dunstan HJ, Mill AC, Stephens S, Yates LM, Thomas SH. Pregnancy outcome following maternal use of zanamivir or oseltamivir during the 2009 influenza A/H1N1 pandemic: a national prospective surveillance study BJOG. 2014 Jun;121(7):901-6.
Wollenhaupt M, Chandrasekaran A, Tomianovic D. The safety of oseltamivir in pregnancy: an updated review of post-marketing data. Pharmacoepidemiol Drug Saf. 2014 Oct;23(10):1035-42.